Table 1.
Patients and study components
Study patients | Tumour tissues | ||
BRAF V600E mutant | BRAF V600E mutation negative or unanalysable | ||
Blood sample (ctDNA analysis) |
BRAFV600E mutant | Primary analysis part | Liquid biopsy part |
BRAFV600E mutation negative or not evaluated | Primary analysis part | Not enrolled in the study |
ctDNA, circulating tumor DNA.